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Abstract
Background: The purpose of this study was to prove the hypothesis that C-reactive protein (CRP) and nerve
growth factor (NGF) may be potential biomarkers for lower urinary tract disorders and may be able to distinguish
between micturition dysfunctions of different origin in dogs with spinal cord diseases. NGF- and CRP-
concentrations were measured in serum and urine samples using specific ELISA-Kits. Results in urine were
standardized by urine-creatinine levels.
Results: CRP in serum was detectable in 32/76 and in urine samples in 40/76 patients. NGF could be measured in
all serum and in 70/76 urine samples. Urinary CRP concentrations were significantly higher in dogs with micturition
dysfunction (p = 0.0009) and in dogs with different neurological diseases (p = 0.0020) compared to the control
group. However, comparing dogs with spinal cord disorders with and without associated micturition dysfunction
no significant difference could be detected for NGF and CRP values in urine or serum samples. Additionally, levels
did not decrease significantly, when measured at the time when the dogs regained the ability to urinate properly
(urinary NGF p = 0.7962; urinary CRP p = 0.078). Urine samples with bacteria and/or leukocytes had no significant
increase in urinary NGF (p = 0.1112) or CRP (p = 0.0534) concentrations, but higher CRP-levels in urine from dogs
with cystitis were found compared to dogs without signs of cystitis.
Conclusions: From these data we conclude that neither CRP nor NGF in urine or serum can be considered as
reliable biomarkers for micturition disorders in dogs with spinal cord disorders in a clinical setting, but their
production might be part of the pathogenesis of such disorders. Significantly higher levels of CRP could be found
in the urine of dogs with micturition dysfunctions compared to control dogs. This phenomenon could potentially
be explained by unspecific extrahepatic CRP production by smooth muscle cells in the dilated bladder.
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Background
Complications with the voluntary control of micturition
are commonly observed in disorders of the nervous
system [1] and can worsen the prognosis in interverte-
bral disc diseases [2], a common neurological disorder in
dogs [3]. Intervertebral disc disease cranial to the lum-
bosacral level can affect the voluntary voiding process
[4] and might result in a detrusor-urethral dyssynergia
with an areflectic bladder and urine retention [5].
Micturition disorders may be caused by the neurological
disorder itself or an associated cystitis [6] precipitated by
bacterial infections [7]. Escherichia coli is the most com-
mon isolate from canine urine [8, 9]. The pathogens
reach the bladder from either gastrointestinal sources or
the skin via the urethra [7]. The clinical signs are either
pollakiurie, stranguria, dysuria, hematuria, inappropriate
urination or periuria [10] and are difficult to distinguish
from a neurogenic induced micturition disorder. Dogs
with spinal cord injuries display a high prevalence of
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developing urinary tract infections [11, 12] even after
recovery of voluntary urination [13].
Therefore, a biomarker helping to distinguish between
neurogenic and non-neurogenic micturition disorders
might be useful for pathogenesis studies and initiating
appropriate treatment.
A biomarker should be an indicator for a specific disease
and is supposed to identify the presence, severity, progres-
sion and the response to a specific treatment [14, 15].
Specific cells, enzymes, hormones, genes or gene products
can be used as biomarkers [16]. The measurement can be
performed in different tissues or body fluids [14, 16]. Two
of the urinary biomarkers identified in human medicine
so far are the nerve growth factor (NGF) and the
C-reactive protein (CRP) [16].
NGF being a well-known neurotrophin, plays an im-
portant role in conditions of inflammatory and neuro-
pathic pain [17, 18]. It is responsible for the growth,
survival and development of neural cells, as well as the
regulation of neural plasticity in the micturition pathway
[19]. NGF is produced by urethral cells and cells of the
detrusor muscle [20]. Different studies show that NGF is
involved in the development of neurogenic bladder over-
activity at the spinal level following the disruption of
supraspinal micturition control after spinal cord injury
[19]. Raised NGF levels in serum could be found in blad-
der dysfunctions [21]. There are several studies in
humans on NGF as a urinary biomarker [22] showing in-
creased NGF levels in patients with urinary tract disor-
ders [21, 23, 24].
CRP is an acute-phase protein, mainly produced in the
liver and elevated after infection, inflammation or trauma.
The CRP concentration rises depending on the tissue
damage [25]. In human studies CRP in serum is increased
in patients with lower urinary tract disorders and it corre-
lates with the severity of clinical signs [26, 27]. In dogs,
CRP in serum can be used as an indicator of inflammatory
response to experimentally induced cystitis [28].
Therefore, we hypothesize that CRP and NGF are
measurable in serum and urine samples and can be
used as biomarkers in either serum or urine to distin-
guish between micturition disorders caused by neuro-
logic dysfunctions or bacterial cystitis in dogs with
spinal cord disease.
Results
76 dogs were included in the study. The patients were
categorized into four different groups (Table 1).
Diseases included in the study are summarized in
Table 2. Urinary CRP could not be detected in each pa-
tient. The highest levels were found in dogs with spinal
cord disorders and micturition problems. 80 % of the
dogs in the control group, 64 % with different neuro-
logical disorders, 41 % with spinal cord disorders with
micturition problems and 29 % with spinal cord disor-
ders without micturition problems had detectable CRP
values. In detail, urinary CRP was measurable in 16/20
dogs of the control group with a mean concentration of
1.08 ng/ml (range: 0–1.76 ng/ml). After normalizing
CRP to creatinine the mean ratio was 0.01 CRP/Crea
(range: 0–0.02 CRP/Crea) (Table 3). In 9/14 of the pa-
tients within the group of different neurological disor-
ders urinary CRP was measurable with a mean
concentration of 2.21 ng/ml (range: 0–11.39 ng/ml) and
after normalizing to creatinine the mean ratio accounted
for 0.04 CRP/Crea (range: 0–0.26 CRP/Crea) (Table 3).
In the group “spinal cord disorders without micturition
problems” CRP was measurable in 4/15 dogs with a
mean concentration of 1.45 ng/ml (range: 0–14.91 ng/ml)
and after normalizing to creatinine the mean ratio was
0.02 CRP/Crea (0–0.17 CRP/Crea) (Table 3). CRP was
measurable in 11/27 patients of the group with the spinal
cord disorders with micturition problems with a mean
concentration of 9.22 ng/ml (0–131 ng/ml) and after
normalizing to creatinine a mean ration of 0.12 CRP/Crea
(0–1.14 CRP/Crea) was detected (Table 3).
Serum CRP could be detected in 4/20 patients in
the control group with a mean of 946 ng/ml (range:
0–6820 ng/ml) (Table 3). The mean level in 7/14
patients with neurological disorders was 22,452 ng/ml
(range: 0–208,658 ng/ml) (Table 3). The wide range of
Table 1 Categorization of the dogs into four different groups
Groups N
1 Different neurological disorders (ND) 14
2 Spinal cord disorders without micturition problems (SC) 15
3 Spinal cord disorders with micturition problems (SC MD) 27
4 Healthy dogs (control) 20
Table 2 Different diseases included in the study
Disease N ND SC SCMD
Idiopathic epilepsy 5 5
Cryptogenic epilepsy 1 1
Meningoencephalitis 3 3
Steroid-responsive meningitis-arteritis 1 1
Vestibular disease 2 2
Neoplasia intracranial 1 1
Polyneuropathy 1 1
Intervertebral disc herniation 39 15 24
Myelitis 1 1
Vertebral dislocation 2 2
Total 56
Distribution of the diseases in the different groups (N = number): neurological
disorders (ND), spinal cord disorders without micturition dysfunction (SC),
spinal cord disorders with micturition dysfunction (SCMD)
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the values was caused by including dogs with inflam-
matory CNS diseases. One dog suffering from steroid-
responsive meningitis-arteritis displayed the highest
value (208,658 ng/ml). This sample was additionally
used as a positive control [29] to evaluate the ELISA
test, since CRP was not measurable in all serum
samples. In 9/15 dogs with spinal cord disorders
without micturition problems CRP was measurable
with a mean concentration of 14,764 ng/ml (range:
0–92,035 ng/ml) and in 12/27 dogs with micturition
problems a mean concentration of 9235 ng/ml (range
0–81,719 ng/ml) could be detected (Table 3).
In all of the 20 patients in the control group urinary
NGF was measurable and ranged between 7.17-250 pg/ml
(mean 76.60 pg/ml). After normalizing to creatinine a
mean ratio of 0.50 NGF/Crea (range 0.06 - 3.00
NGF/Crea) could be found (Table 3). In 13/14 pa-
tients with different neurological disorders NGF was
measurable with a mean concentration of 31.98 pg/ml
(range 0–150 pg/ml) and after normalizing to creatinine
the mean ratio was 0.61 NGF/Crea (range 0–2.41 NGF/
Crea) (Table 3). Urinary NGF mean value was 63.24 pg/ml
(range 0–198 pg/ml) in 13/15 patients with spinal
cord disorders without micturition problems (Table 3),
the mean NGF/Creatinine ratio was 1.00 NGF/Crea
(range 0–3.43 NGF/Crea) (Table 3). In 24/27 dogs
with micturition problems the mean concentration of NGF
was 58.11 pg/ml (range 0–250 pg/ml). The range of the
ratio after normalizing to creatinine was 0–4.40 NGF/Crea
with a mean of 0.73 NGF/Crea (Table 3).
Serum NGF was detectable in all of the analyzed serum
samples. The mean concentration of the control group
was 179 pg/ml (range: 104–250 pg/ml), of different neuro-
logical disorders 164 pg/ml (range: 40–250 pg/ml), of the
spinal cord disorders without micturition problems
166 pg/ml (range: 24.77-250 pg/ml) and the spinal cord
disorders with micturition problems showed a mean con-
centration of 167 pg/ml (range: 46–250 pg/ml) (Table 3).
In the first group including all dogs, significant differ-
ences measuring the CRP/Crea-ratio could be found be-
tween the spinal cord disorders without micturition
problems and the control group (p = 0.0118) as well as
with different neurological disorders (p = 0.0445). No
further significant differences could be detected.
The CRP levels in serum were significantly different in
the control group and the spinal cord disorders without
micturition problems (p = 0.0181) (Table 4), no further
significant differences could be evaluated (Table 4).
Additionally, we determined the significances between
the concentrations of CRP/Crea in the different groups
in the urine only within measurable samples (Fig. 1 and
Table 4). Significant differences could be detected be-
tween the healthy control group and the neurological
disorders (p = 0.0020) as well as the spinal cord disorders
Table 3 C-reactive protein and nerve-growth-factor levels in urine and serum samples
CRP urine ng/ml CRP/Crea urine CRP serum ng/ml NGF urine NGF/Crea urine NGF serumpg/ml
Control 1.08 (0–1.76) 0.01 (0–0.02) 946 (0–6820) 76.60 (7.17-250) 0.50 (0.06-3.01) 179 (104–250)
Neurological Disorders 2.21 (0–11.39) 0.04 (0–0.26) 22452 (0–208658) 31.98 (0–150) 0.61 (0–2.41) 164 (40–250)
SC 01.45 (0–14.91) 0.02 (0–0.1721) 14764 (0–92035) 63.24 (0–198) 1.00 (0–3.43) 166 (24.77-250)
SC MD 9.22 (0–131) 0.12 (0–1.1462) 9235 (0–81719) 58.11 (0–250) 0.73 (0–4.40) 167 (46–250)
C-reactive protein (CRP) and nerve-growth-factor (NGF) levels in urine and serum samples (mean, range in brackets), CRP/Creatinine and NGF/Creatinine ratios in
the different groups: control group (n = 20), neurological disorders (n = 14), spinal cord disorders without micturition dysfunctions (SC) (n = 15) and spinal cord
disorders with micturition dysfunctions (SC MP) (n = 27)











Control Group vs Neurological Disorders 0.0020* 0.2510 0.0670 0.6119 0.6450
Control Group vs SC 0.5391 0.0118* 0.0181* 0.4334 0.9591
Control Group vs SC with micturition dysfunction 0.0009* 0.4010 0.1113 0.8546 0.6484
Neurological Disorders vs SC without micturition dysfunction 0.6997 0.0445* 0.4503 0.4712 0.7315
Neurological Disorders vs SC with micturition dysfunction 0.4033 0.3369 0.8576 0.7207 0.9778
SC without micturition dysfunction vs SC with micturition dysfunction 0.3961 0.2837 0.3401 0.4620 0.8298
Cystitis vs No cystits 0.0534 0.1112
Dogs unable to urinate vs Dogs with normal voiding 0.0778 0.7962
P-values of the different concentrations of C-reactive protein (CRP) and nerve growth factor (NGF) in serum and after normalizing to creatinine (CRP/ Crea; NGF/
Crea) in urine samples for the different groups. Measurements including all CRP/Crea values are shown in the column “CRP/Crea urine all”. Calculations of samples
only with detectable values are shown in the column “CRP/Crea Urine”. P-values comparing dogs with spinal cord disorders and associated micturition dysfunction
with (cystitis) and without cystitis (no cystitis) and dogs regaining the ability to urinate (dogs with normal voiding) are shown in the last rows. Significances are
highlighted with an asterisk (*).Spinal Cord disorders (SC)
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with micturition problems (p = 0.0009). No significant
difference could be found between spinal cord disorders
with and without micturition problems (p = 0.3961).
However, the highest values of CRP/Crea-ratios occurred
in dogs with micturition problems.
No significant differences could be detected in the
urine of NGF/Crea ratios and the NGF levels in serum
in the four different groups (Fig. 2 and Table 4).
Neither urinary NGF/Crea (p = 0.7962) nor CRP/Crea
(p = 0.0778) showed significantly decreased levels after
dogs with micturition disorders regained the ability to
urinate (Table 4).
The urine examination revealed leukocytes (8/10) or
bacteria and leukocytes (2/10) in 10 samples of the 27
dogs with micturition dysfunction. CRP/Crea and
NGF/Crea values of dogs with cystitis were higher
than in dogs without bacteria and/or leukocytes in the
urine. However, this increase was not statistically signifi-
cant (NGF/Crea p = 0.1112 and CRP/Crea p = 0.0534)
(Fig. 3 and Table 4).
Discussion
In the current study the hypothesis had to be proven,
that CRP or NGF are measurable in urine and serum
samples of dogs and that these two proteins may be in-
volved in the pathogenesis of micturition disorders. The
aim of the study was to establish CRP and NGF as bio-
markers helping to distinguish between neurogenic and
non-neurogenic micturition disorders. In this study we
concentrated on micturition disorders caused by diseases
of the spinal cord and associated bacterial cystitis. In-
deed, CRP and NGF are measurable with specific, com-
mercially available ELISA kits in both, urine and serum
of dogs as described before [24, 30]. Urine samples were
compared to creatinine values of the urine to overcome
the different dilutions between the samples [24].
However, the second part of the hypothesis could not
be proven. No differences of NGF in serum or urine
could be found between the different groups of neuro-
logical disorders and the control group.
NGF levels can rise in many different conditions such
as neurologic diseases, endocrinological disorders and
diseases of the immune system [31]. It is produced by
many different cells, including urothelial cells, smooth
muscle cells and mast cells [21]. Urinary NGF in
particular was examined in lower urinary tract disorders
[23]. HT Liu and HC Kuo [21] demonstrated that serum
Fig. 1 C-reactive protein/ creatinine ratios in urine. C-reactive protein/
creatinine (CRP/Crea) concentrations: significant differences (*)
between the control group (healthy dogs n = 20) and different
neurological disorders (n= 14) (ND) (p= 0.0020) as well as spinal cord
disorders with micturition dysfunction (n= 15) (SC MD) (p = 0.0009). The
boxplots are indicating minimums and maximums, lower and upper
quartiles, and medians
Urine Serum
Fig. 2 Ratios of nerve growth factor/ creatinine in urine and nerve growth factor levels in serum in the different groups. Ratios of nerve
growth factor/creatinine in urine (NGF/Crea) and nerve growth factor levels in serum (NGF Serum) in the different groups: control group
(healthy dogs; n = 20), neurological disorders (ND; n = 14), spinal cord disorders without micturition dysfunctions (SC; n = 15) and spinal
cord disorders with micturition dysfunction (SC MD; n = 27). No significant differences could be detected. The boxplots are indicating
minimums and maximums, lower and upper quartiles and medians
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and urine NGF levels were increased in humans suffer-
ing from interstitial cystitis and bladder pain syndrome,
but no correlation could be found between serum and
urinary NGF and the clinical signs. The authors suggest
that other systemic disorders are also involved and influ-
ence the NGF-levels, especially the levels in serum [21].
In the current study, we tried to rule out other systemic
diseases by routine blood examination and different im-
aging techniques such as ultrasound and radiographs of
abdomen and thorax to exclude such an influence.
Urinary NGF levels were also found to be increased in
cerebrovascular events and correlate with the severity of
neurological impairment but not with urinary tract dys-
functions [32]. In our study dogs with mild and severe
spinal cord injury were included leading most probably
to the high range of the values and overlap between the
groups.
The detected high variability of NGF-levels could be ex-
plained by comparing with the following studies. A study
with rats experiencing stress showed increased NGF-values
in serum [17]. In the current study, dogs with neurological
dysfunctions had to be examined in the clinic. It could be
expected that these dogs were suffering from stress because
of their disease and the medical intervention, which could
interfere with the production of NGF.
In human reports urine has been collected, when the
bladder was full and the patients had a strong desire to
void. NGF in urine increases physiologically while blad-
der stretching in healthy people [33]. In dogs it is diffi-
cult to standardize the urine collection according to
those factors. However, urine samples were always taken
from a filled bladder either through spontaneous voiding
(walking the dog only when the bladder was filled), man-
ual expression or cystocentesis to overcome the influ-
ence of heterogenous bladder stretching as much as
possible.
NGF in urinary bladder biopsies of rats with spinal
cord injuries was found to decrease four days to four
weeks after injury, whereas the amount of NGF in-
creased five to six weeks after the injury [34]. The
mRNA-levels of total urinary bladder NGF decreased
significantly in acute or chronic cyclophosphamide-
induced cystitis compared to control animals. In the
current study urine and serum collection was performed,
when the dogs were presented in the clinic, therefore
standardization according to the onset of the clinical
signs was not feasible. The dogs had been suffering from
neurological signs and/or micturition disorder for a vari-
able amount of time. This well-known shortcoming of
clinical studies could be a reason for measuring a wide
range of NGF-values.
In conclusion, NGF cannot be developed to serve as a
specific biomarker for severity of micturition disorders
in a clinical setting shown by the results of the current
study and the fact that NGF secretion in urine and espe-
cially serum can be influenced by many different factors.
CRP is an acute-phase protein, which is mainly pro-
duced by the liver and is raised in conditions of inflam-
mation and tissue damage [25].
In a study performed by Chuang et al. (2010) the au-
thors demonstrated higher serum levels in humans with
lower urinary tract disorders (overactive bladder syn-
drome), but urinary CRP and mRNA expression of CRP
in bladder biopsies were barely detectable. Detection of
elevated urinary CRP has been reported before in dogs
with renal disease caused by leishmaniasis [35],
babesiosis [36] and pyometra [37]. A time-resolved
immunofluorimetic assay was used to determine the
urinary CRP concentration in dogs with leishmaniasis
[35], whereas urine samples of dogs with babesiosis and
pyometra were analyzed using an ELISA-system as in
the current study [36] .
Fig. 3 Spinal cord disorders with micturition dysfunction. Values of C-reactive protein/creatinine ratio (CRP/Crea) and nerve-growth factor/ creatinine
ratio (NGF/Crea) of dogs with spinal cord disorders with micturition dysfunction (n = 27). No significant difference in CRP/Crea (p = 0.0534) or NGF/Crea
(p = 0.1112) could be detected within the group of dogs with micturition dysfunctions with (n = 10) or without cystitis (n = 17). However,
higher concentrations could be found in dogs with cystitis in the NGF and CRP measurements. The boxplots are indicating minimums and
maximums, lower and upper quartiles, and medians
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In our study CRP could not be detected in each urine
sample, even the study design, control probes and the
above mentioned measurements are proof that CRP is
measurable in urine of dogs using an ELISA. Evaluating
detectable urine samples only a significant higher con-
centration of CRP/Crea-levels could be found comparing
the control group and different neurological disorders
and the control group with spinal cord disorders with
micturition problems. Measurements in the group spinal
cord disorders without micturition problems displayed
the widest range. In this group the severity of neuro-
logical/motor dysfunction varied the most. Additionally,
CRP/Crea levels in dogs suffering from spinal cord
disorders with micturition dysfunction with cystitis were
higher than in dogs without cystitis. In a study done by
KW Seo, JB Lee, JO Ahn, HW Lee, CY Hwang, HY
Youn and CW Lee [28], dogs with experimentally
induced cystitis showed higher CRP values in serum
than the control group. Since no significances could be
detected in dogs with spinal cord disorders with and
without cystitis, a comparison with a control group of
dogs without neurological dysfunction and cystitis was
abandoned. Such dogs suffered also from systemic dis-
eases, which would have influenced additionally CRP
and NGF concentrations (data not shown).
It is anticipated that many tissues of the body can
produce CRP as a part of their own immune system
defense [38]. Extrahepatic syntheses have been reported
in neuron, atherosclerotic plaques, monocytes and lym-
phocytes. The mechanisms underlying the extrahepatic
synthesis are unknown [38, 39]. In humans CRP can be
produced by coronary artery smooth muscle cells [40].
Therefore, a production of CRP by smooth muscle cells
of the bladder might be involved in the pathogenesis of
micturition disorders.
The highest concentrations can be measured two to
four days after the onset of the disease [41]. The individ-
ual CRP concentrations can vary significantly between
different dogs [42]. S Yamamoto, T Shida, S Miyaji, H
Santsuka, H Fujise, K Mukawa, E Furukawa, T Nagae
and M Naiki [41] reported increased and decreased CRP
serum values in dogs with different disorders such as
enteritis, eye diseases and nephritis. Some of the dogs
whose medical condition had improved after the treat-
ment had increased, others decreased CRP levels [41].
Levels of CRP in serum can increase after surgery.
Moreover, the degree to which the levels rise, corre-
sponds to the surgical trauma [43]. In our study some
patients underwent surgical treatment and others did
not. This could be a reason for different serum CRP
values specifically the high range of the CRP levels.
However, a diagnostic biomarker for use in a clinical
setting should overcome such differences in treatment
of individual patients with spinal cord disorders.
Conclusions
In conclusion, CRP and NGF are measureable in both
urine and serum of dogs. Levels of CRP in the urine of
dogs with spinal cord disorders with micturition prob-
lems were elevated. However, not all dogs with mictur-
ition disorders had detectable CRP values. No significant
differences of CRP and NGF in serum or urine in the
diseased groups could be detected. Therefore, it cannot
be recommended to develop CRP and NGF as reliable
biomarkers in micturition disorders in a clinical setting.
However, these proteins could be valuable for pathogen-
esis studies or for control examinations of single patients
in treatment studies.
Methods
Study design and animals
Paired urine and serum samples were collected from 76
dogs with different neurological disorders and from con-
trol dogs at the Department of Small Animal Medicine
and Surgery, University of Veterinary Medicine Hannover,
Germany. The study was performed according to the eth-
ical rules of the Lower Saxony State Office for Consumer
Protection and Food Safety, Germany, animal experiment
number: 33.4-42502-04-13A374. An owners’ permission
was granted for all dogs. The following breeds were in-
cluded: mixed breed (n = 17), Dachshund (n = 10), Beagle
(n = 8), Bernese Mountain Dog (n = 6), Labrador (n = 5),
French bulldog (n = 4), Golden Retriever (n = 3), Jack
Russell Terrier (n = 2), Shepherd (n = 3), Giant Schnauzer
(n = 2), Small Münsterländer (n = 1), Boxer (n = 1),
Bolonka Zwetna (n = 1), Miniature Schnauzer (n = 1),
Weimaraner (n = 1), Saint Bernard dog (n = 1), Old English
Sheepdog (n = 1), Swiss Mountain Dog (n = 1), Pekingese
dog (n = 1), Chihuahua (n = 1), Shi Tzu (n = 1), Bracke
(n = 1), German wirehaired pointer (n = 1). The mean
age of the dogs was 5.6 years (+/− 2.8 years) and the
average weight was 19.8 kg (+/−13 kg). 29 dogs were
male, 21 castrated-male, 7 female and 19 spayed
female.
Paired urine and serum samples were collected from
patients with different neurological disorders and from
the control dogs. The clinical diagnosis was established
using a combination of clinical examination, neuro-
logical examination, blood and urine analysis, magnetic
resonance imaging (52/76) and evaluation of cerebro-
spinal fluid samples (48/72). In all dogs regular clinical
and laboratory control examinations were performed to
rule out concurrent diseases.
The patients were categorized in 4 different groups
(Table 1): healthy dogs (n = 20); different neurological dis-
orders except spinal cord disorders (Table 2) (n = 14);
spinal cord disorders with normal micturition (n = 15);
spinal cord disorders with micturition problems (n = 27)
(Table 5); [44] out of the 27 dogs with micturition
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problems, 10 urine samples were taken in a follow up
study, when the dogs regained the ability to void. “Nor-
mal” micturition was assumed, when dogs with spinal
cord disorders had spontaneous voiding when the bladder
was filled and they could walk outdoors. Dogs were con-
sidered to be healthy, when clinical and neurological ex-
aminations were normal and no abnormalities in blood
and urine analysis were observed.
Sample collection
Urine samples were collected after spontaneous voiding,
manual expression or cystocentesis and immediately an-
alyzed. All urine samples of dogs with normal mictur-
ition were taken after spontaneous voiding, urine
samples of dogs with micturition disorders were taken
after manual expression (n = 12) or cystocentesis (n =
15). To rule out or to diagnose cystitis all urine samples
were analyzed with a colorimetric urine analysis reagent
test stripe (Urine stripes, Roche Diagnostics GmbH,
Mannheim, Germany). Samples with leukocytes and/or
bacteria in urine sediment analysis were considered
dogs with cystitis. The specific gravity was measured
with a refractometer (Manual Handrefractometer,
A.KRÜSS Optronic GmbH, Hamburg, Germany). The
urine creatinine level was measured to normalize CRP
and NGF levels using Cobas C311 Analyzer (Roche
Diagnostics GmbH, Mannheim, Germany). Urine and
serum samples were centrifuged at 1000 rpm for
10 min and frozen at −20 °C until analyzed.
Analysis of NGF
Urinary and serum NGF concentrations were determined
using an immunosorbent assay system (NGF EMAX ®Im-
munoAssay System- ELISA Test Kit, Madison, WI, USA).
This assay was evaluated for the use of canine samples
[24, 30]. The assay had a minimum sensitivity of 7.8 pg/
ml, values above 250 pg/ml cannot be quantified and was
performed according to the manufacturer’s instructions.
Serum samples were diluted 1:50, urine samples were not
diluted. Values that were above 250 pg/ml were counted
as 250 pg/ml, values lower than the detection range as
zero. All samples were run in duplicates and the mean of
these two values was used for further evaluation.
Analysis of CRP
CRP levels in urinary and serum samples were measured
using a commercially available dog specific immunosorb-
ent assay system (dog high- Sensitive CRP ELISA Kit,
Kamiya Medical Company, Seattle, WA, USA), which can
be applied for several biological fluids such as urine. The
detection range was between 3,125 ng/ml and 200 ng/ml.
The assays were conducted according to the manufactures
instructions. The serum samples were diluted 1:1000,
urine samples were diluted 1:2. Results below the detec-
tion limit were counted as zero. None of the samples were
above the detection limit. All samples were run in dupli-
cates and the mean of these two values was used for fur-
ther evaluation.
Statistical analysis
After testing for normal distribution, the Wilcoxon-
Mann-Whitney-Test was used to evaluate potential sig-
nificant differences between the four different groups. To
distinguish between healthy dogs and dogs with cystitis a
t-test was performed. In order to differentiate between
dogs with abnormal micturition and dogs that regained
ability of normal micturition a f-test was performed. To
analyze the number of samples with detectable CRP and
NGF values a Fisher-Yate was used. All data analyses were
conducted with the statistic program package SAS®, ver-
sion 9.2 (SAS Institute, Cary, NC, USA). For all statistical
tests an error probability of p < 0.05 as significance level
was chosen. Statistical calculations were performed twice:
using all data including the patients without measurable
CRP values (counted as zero) and a calculation including
only patients with measurable values. Data of calculated
p-values are summarized in (Table 4).
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